Biweekly Triple Combination Chemotherapy with Gemcitabine, Oxaliplatin, Levofolinic Acid and 5-Fluorouracil (GOLF) Is a Safe and Active Treatment for Patients with Inoperable Pancreatic Cancer

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of chemotherapy

• Publication date

  2008-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1179/joc.2008.20.1.119PMID 18343754
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

  2023cited by this paper
• Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.

  2007cited by this paper
• Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.

  2006cited by this paper
• A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

  2006cited by this paper
• Prognostic factors for survival in pancreatic cancer: a population-based study.

  2006cited by this paper
• Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48‐h infusion of fluorouracil/leucovorin for advanced pancreatic cancer

  2006cited by this paper
• Pancreatic cancer: a review of recent advances

  2006cited by this paper
• Chemotherapy for advanced pancreatic cancer.

  2006cited by this paper
• Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

  2006cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.

  2006cited by this paper
• Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

  2006cited by this paper
• Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased raf-1 ubiquitin-dependent degradation

  2005cited by this paper
• Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

  2005cited by this paper
• Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

  2005cited by this paper
• Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

  2005cited by this paper
• Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer

  2005cited by this paper
• Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

  2005cited by this paper
• Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

  2004cited by this paper
• Molecular-targeted agents in pancreatic cancer.

  2004cited by this paper
• Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in Patients with Different Gastroenteric Malignancies

  2004cited by this paper
• A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma

  2004cited by this paper
• Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients.

  2003cited by this paper
• Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.

  2003cited by this paper
• A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid

  2003cited by this paper
• Update on pancreatic cancer

  2002cited by this paper
• Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

  2002cited by this paper
• Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.

  2002cited by this paper
• Gemcitabine in combination with 5‐fluorouracil with or without folinic acid in the treatment of pancreatic cancer

  2002cited by this paper
• Cellular and molecular pharmacology of oxaliplatin.

  2002cited by this paper
• Gemcitabine‐based therapy in pancreas cancer

  2002cited by this paper
• Pancreatic cancer

  2000cited by this paper
• A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

  2000cited by this paper
• Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.

  1999cited by this paper
• A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

  1999cited by this paper
• A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors

  1998cited by this paper
• Chemotherapy in advanced pancreatic cancer

  1997cited by this paper
• Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.

  1995cited by this paper

• SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217).

  2026cites this paper
• Correction to: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

  2018cites this paper
• Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

  2018cites this paper
• Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy

  2017cites this paper
• Simplified/Same Day(s)-GOLF as First-line Treatment of Metastatic Carcinoma of Unknown Primary (CUP), Suggestive of Pancreatobiliary Tumors.

  2016cites this paper
• Targeted Therapies For Intestinal Tumorigenesis

  2015cites this paper
• Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer.

  2015cites this paper
• Intestinal Tumorigenesis

  2015cites this paper
• Advanced stage pancreatic cancer: novel therapeutic

  2014cites this paper
• Advanced stage pancreatic cancer: novel therapeutic options

  2014cites this paper
• Neoadjuvant therapy in resectable pancreatic cancer: a critical review.

  2013cites this paper
• Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.

  2013cites this paper
• Neoadjuvantní terapie karcinomu slinivky břišní

  2012cites this paper
• Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen

  2012cites this paper
• Three-drug combination regimen in pancreatic cancer treatment: are we there yet?

  2011cites this paper
• Effects of Radiation Therapy on Myocardial Cell Integrity and Pump Function: Which Role for Cardiac Biomarkers?

  2010cites this paper
• Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?

  2010cites this paper
• Current world literature. Pain: cancer.

  2009cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2008cites this paper